

Facts about **Stroke** Rehabilitation

15 million people suffer a stroke each year

Stroke is among the **leading causes** of serious, **long-term disability** worldwide

5 million people have permanent disability due to stroke every year

80% experience **hemiparesis of the upper limb**

Highly increased number of studies in neurorehabilitation

Focus on **stroke rehabilitation guidelines** in many countries

The **best drug** for stroke recovery Strong recommendations in all guidelines



Strongest recommendation for **Cerebrolysin®**

- **1st EAN guideline** for neurorehabilitation after stroke
- **Highest quality** evidence
- **Best results** in all domains
- **Proven safety**

Austria



Cerebrolysin® is the **best assessed compound**

- 1st evidence based Austrian Rehabilitation Guideline
- **Cerebrolysin®** is the **only officially named drug**

Canada



Cerebrolysin® - The only 100% recommended drug*

- The only positive **1a ranking** in motor function domain
- Best ranked drug in ADL**

Germany




Cerebrolysin® is the **best ranked medication**

- Confirmation of **CARS treatment** concept
- Recovery of arm function has a significant impact on quality of life and ADL

Highest evidence in relevant stroke rehabilitation domains

Domains	Motor Function	ADL	Quality of life
Study results Cerebrolysin®	Improvement of motor functions	Enhancement of Activities of daily living	Increase quality of life
Cerebrolysin® recommended			
 Best results in all domains			

Recommended treatment of **Cerebrolysin®**



*in Clinican's handbook without any negative comments
** Activities of daily living

Cerebrolysin® included in guidelines of top reference countries



AUSTRIA



CANADA



GERMANY



- Different Guideline Committees
- Different Timepoints
- Different Composition

All came to the same conclusion:
Cerebrolysin® is the best drug for stroke recovery!



References:



1. Hillis, Argye E., and Donna C. Tippet. "Stroke recovery: Surprising influences and residual consequences." *Advances in medicine* 2014 (2014).
2. Hatem, Samar M., et al. "Rehabilitation of motor function after stroke: a multiple systematic review focused on techniques to stimulate upper extremity recovery." *Frontiers in human neuroscience* 10 (2016): 442.
3. Austrian Guideline: https://www.xn--gsf-rna.at/wp-content/uploads/2016/11/Positionspapier-2018_OEGSF_neurologisch.pdf
4. Canadian Guideline: http://www.ebrsr.com/sites/default/files/EBRSR%20Handbook%20Chapter%204_Upper%20Extremity%20Post%20Stroke_ML.pdf
5. DGNR Guideline: <https://www.awmf.org/leitlinien/detail/II/080-001.html>
6. Beghi, Ettore, et al. "European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke." *European Journal of Neurology* (2021).

Copyright © 2021 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria

ABBREVIATED PRESCRIBING INFORMATION – Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type, Vascular dementia, Stroke, Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorization Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.

EVER Pharma GmbH
Oberburgau 3
4866 Unterach
Austria

CERE/INT/09/2021/18



Cerebrolysin® Strongest recommended drug for stroke recovery

Confirmed by multiple guidelines



Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.

Quality from
Austria.

Cerebrolysin® included in EAN guidelines Strongest recommendation for Cerebrolysin®



Cerebrolysin® included in
PAN-EUROPEAN GUIDELINE!



This guideline found **sufficient evidence** to recommend use of **Cerebrolysin®** in moderate–severe cases, as an add-on therapy **to standard rehabilitation, initiated in the first 7 days after stroke...**



EAN = largest neurological society
worldwide, with 45.000 members